Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 211 Triple Negative Breast Neoplasms 32 Stomach Neoplasms 32 Inflammatory Breast Neoplasms 21 Esophageal Neoplasms 16 Carcinoma, Hepatocellular 15 Lymphoma, Large B-Cell, Diffuse 9 Sarcoma 8 Neoplasms 8 Non-Muscle Invasive Bladder Neoplasms 6 Urinary Bladder Neoplasms 5 Pancreatic Neoplasms 5 Liver Neoplasms 5 Breast Neoplasms, Male 5 Adenocarcinoma Of Esophagus 5 Ovarian Neoplasms 4 Lymphoma 4 Testicular Neoplasms 3 Primary Breast Cancer 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pathologic Complete Response 3 Hemangiosarcoma 3 Gallbladder Neoplasms 3 Carcinoma, Ductal, Breast 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Recurrence 2 Prostatic Neoplasms 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neoplastic Cells, Circulating 2

Interventions

Neoadjuvant Therapy 1 Lapatinib 1 Epirubicin 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Oesophagogastric Cancer × Epirubicin × Clear all

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡